FDA Follows Industry Lead to Shorten Time to Market

Oct 31st, 2012 | By | Category: FDA
October 30, 2012 ~    The FDA has issued the new rules for medical device makers to speed up the time it takes for medical devices to make it to market.

Earlier this year industry agreed to pay $595 million over 5 years to the FDA as part of its operating budget. In exchange, the FDA would reduce the average time it takes to bring a device onto the market under the 510(k) approval system from 150 days to 124 by the year 2017.

The agreement was reached under the Medical Device User Fee Amendments of 2012 (MDUFAIII).

The 510(k) approval process has been responsible for allowing most defective medical devices onto the market including metal-on-metal hips and vaginal mesh.

Safety and efficacy clinical trials are not required under 510(k). The device makers file paperwork notifying the FDA they plan to market the device and claim it is the “substantial equivalent” of a device already on the market known as the “predicate device.”

Mass Device (here) reports that 90 percent of medical devices should be cleared for marketing within 90 days and 98 percent should be on the market within 150 days.

Preliminary acceptance review will be conducted within 15 calendar days of receiving the 510(k) application to market a device.

MDUFA authorizes the FDA to hire more personnel to better handle the extra load to meet these time frames.

Industry has long complained that it takes too long to bring a product to market, even though, under 510(k), industry gets a pass because it does not have to provide data on expensive, time-consuming clinical trials.

An Institute of Medicine report in 2011 (here) called the 510(k) approval process “fatally flawed.”

Here is the FDA guidance for the years 2012 through 2017.

MDND reported (here) on MDUFA for Another Five Years last August.

User fees were established by Congress in 2002 and are set under the Food Drug & Cosmetic Act, depending on each different type of submission.

However consumer groups argue that MDUFA III gives medical device companies a fast track avenue to approvals for some products in exchange for the higher user fees.

Consumer Union’s Safe Patient Project argued that the politically powerful medical device industry successfully blocked much needed patient protections from the House and Senate versions of MDUFA. See background story here.

What did survive in MDUFA III was an ability by the FDA to reclassify problem devices once the agency realizes there is a problem with a defective device.  That also means the future applications of a similar medical device will be more heavily scrutinized.

Also still alive is a requirement that the FDA issue regulations within six months to establish a Unique Device Identification (UDI) System for life sustaining implantable medical devices. The UDI system must be implemented within two years of finalizing the regulations.

It is not unlike a VIN number on your vehicle that allows a car manufacturer to alert you if there is a recall and to track the car to see if the necessary improvements have been made. #

 

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
Tags: , , , , , , , , , , ,

One Comment to “FDA Follows Industry Lead to Shorten Time to Market”

  1. Carmel Berry says:

    Awesome Jane… you are the best investigative journalist! I am going to send this news story right now to our health minister in New Zealand.. Tony Ryall.

    tony.ryall@national.org.nz
    please.. anyone else in the world join the rally (Rryally) to make New Zealand health authorities look at Mesh issues and the time bomb waiting for our NATIONAL health system.. we have a law against suing doctors or manufacturers. We have a no claim, no blame system.,. sadly only about half of the claims on our compensation system are accepted. Sadly every one else silenced.

Leave a Comment

We hope you find this a helpful resource. National News Editor, Jane Akre, began MDND with the hope of providing the latest news, information and perspective from the regulatory, industry and patient point of view, something that goes under-reported in much of the coverage of medical devices. The public is just now becoming aware that many devices do not undergo the same scrutiny as prescription drugs and are instead grandfathered in under an FDA loophole that has gone largely unchanged since the 1970s. As a result, patients become the post-market clinical trial subjects, and many suffer devastating and permanent injuries.